British cancer charity delivering care, information, and financial support
A Japanese approval for Telomelysin offers a gentler option for esophageal cancer patients ineligible for surgery. Other studies show CAR T-cell therapy remains transformative for certain cancers, while nanotechnology and immunotherapies highlight ongoing progress with meaningful patient impact.
[Synopsis will be inserted here]